COPD is a big health problem, causing over 138,000 deaths in the U.S. in 2021. For those with COPD who keep getting worse, a new hope has come. Nucala (mepolizumab), a monthly shot, was approved in May 2025. It’s a big step forward for treating eosinophilic COPD.
COPD patients face many challenges, but new treatments offer hope. Nucala fights the inflammation that makes COPD worse. It’s a new way to manage the disease. For more on new COPD treatments, check out WebMD for expert advice and facts.
Key Takeaways
- Nucala (mepolizumab) is a once-monthly injectable biologic approved for eosinophilic COPD.
- It targets type 2 inflammation driving disease progression.
- Nucala reduced COPD exacerbations by 30% to 35% in clinical trials.
- Common side effects include injection-site reactions.
- Nucala represents a significant advancement in COPD treatment.
What is Nucala: The First FDA-Approved Monthly Injection for COPD
Nucala is changing how we treat COPD with its monthly injection. Made by GlaxoSmithKline (GSK), it’s approved for severe asthma and some COPD cases.
We’ll dive into what Nucala is, how it works, and the trial data that led to its approval.
Mepolizumab’s Breakthrough in COPD Treatment
Nucala uses mepolizumab, a drug that blocks IL-5. IL-5 is linked to eosinophilic inflammation, a big problem in COPD. By stopping IL-5, mepolizumab cuts down on eosinophils and reduces flare-ups.
Key Benefits of Nucala:
- Reduces exacerbations in COPD patients
- Monthly injection regimen for improved adherence
- Targets IL-5 to reduce eosinophilic inflammation
FDA Approval Timeline and Significance
The FDA approved Nucala for COPD after two big trials. These trials showed it cuts down on severe flare-ups. This is a big win for COPD care, giving a new option for those with high eosinophil counts.
About 70% of COPD patients in the US who don’t get better with usual treatments have high eosinophil counts. This means over a million people could benefit from Nucala.
| Trial | Results | Significance |
| MATINEE | Reduced exacerbation rate | Clinically meaningful reduction |
| METREX | Statistically significant reduction in exacerbations | Supported FDA approval |
Nucala is a game-changer for COPD treatment. It’s a targeted therapy that fights the inflammation causing flare-ups.
How Monthly Injections for COPD Work to Reduce Exacerbations
Monthly injections have changed how we treat Chronic Obstructive Pulmonary Disease (COPD). Mepolizumab, found in Nucala, is a key example of this new method.
Targeting IL-5 and Reducing Eosinophilic Inflammation
Mepolizumab targets interleukin-5 (IL-5), a protein that helps make and activate eosinophils. Eosinophils are white blood cells that can cause airway inflammation, leading to COPD attacks. By lowering eosinophil levels, mepolizumab reduces the number and severity of these attacks.
IL-5 is important for eosinophil inflammation. It helps eosinophils grow, live longer, and work better. In COPD patients, IL-5 and eosinophils are often high, causing more inflammation and attacks. By blocking IL-5, mepolizumab cuts down on eosinophil inflammation, helping patients do better.
Clinical Evidence from MATINEE and METREX Trials
The MATINEE and METREX trials have shown mepolizumab’s effectiveness in lowering COPD attacks. These studies have given us a good look at how mepolizumab helps COPD patients.
- The MATINEE trial found mepolizumab greatly lowers attack rates in COPD patients, making it a good add-on treatment.
- The METREX trial showed mepolizumab cuts attack rates by 21% in eosinophilic COPD patients, a big win for them.
These trials have made mepolizumab a valuable treatment for COPD, mainly for those with eosinophilic COPD. The results from these studies prove Nucala’s monthly injections can reduce attacks and improve patient results.
Conclusion: The Impact and Future of Nucala in COPD Management
The introduction of GSK Nucala is changing how we treat Chronic Obstructive Pulmonary Disease (COPD). It’s the first monthly injection approved by the FDA for COPD. Nucala helps reduce flare-ups and improves how patients feel.
Studies like MATINEE and METREX show Nucala’s success. It targets IL-5 and cuts down on eosinophilic inflammation. This is a big step forward in COPD treatment.
Nucala’s approval is expected to boost the COPD treatment market. It’s set to grow to around $33.03 billion by 2034. With new treatments like Nucala, we can better meet the needs of COPD patients.
At our institution, we’re dedicated to top-notch healthcare. We support international patients and offer the newest COPD treatments. This ensures everyone has access to the best care.
The future of COPD treatment looks promising. Monthly injections like Nucala will likely play a bigger role. We’re excited for the advancements that research and development will bring.
FAQ:
What is Nucala and how is it used in treating COPD?
Nucala (mepolizumab) is an injectable biologic therapy used to reduce exacerbations in severe eosinophilic COPD.
How does Nucala work to reduce exacerbations in COPD patients?
It targets and inhibits interleukin-5 (IL-5), reducing eosinophil levels and airway inflammation.
What is the significance of Nucala’s FDA approval for COPD treatment?
FDA approval recognizes Nucala as the first biologic specifically indicated to reduce exacerbations in severe eosinophilic COPD.
What were the results of the MATINEE and METREX trials for Nucala in COPD?
The trials showed that Nucala reduced moderate-to-severe exacerbations, especially in patients with elevated blood eosinophils.
Is Nucala suitable for all COPD patients?
No, it is indicated only for severe eosinophilic COPD not controlled by standard therapy.
How is the eosinophil count used to determine eligibility for Nucala treatment in COPD?
Patients with blood eosinophil counts ≥150 cells/µL at initiation or ≥300 cells/µL in the past year are more likely to benefit.
Are there other treatments available for COPD besides Nucala?
Yes, standard treatments include inhaled bronchodilators, corticosteroids, oxygen therapy, pulmonary rehab, and other biologics.
How is Nucala administered?
Nucala is given as a subcutaneous injection every 4 weeks.
What is the role of GSK in the development of Nucala?
GlaxoSmithKline (GSK) co-developed and markets Nucala for severe eosinophilic asthma and COPD.
References:
National Center for Biotechnology Information. Evidence-Based Medical Insight. Retrieved from https://pubmed.ncbi.nlm.nih.gov/16113461/
Departments
Related Videos
Our Doctors
News
